A trial treatment for peanut allergy has attracted attention in the media, with a recent Washington state publication highlighting California-based Aimmune Therapeutics Inc.’s “AR101” as a potential immunotherapy with the ability to impact allergen-specific T cells. Read More »
Biothera Pharmaceuticals Inc. recently announced that the patient dosing has begun in a Phase 1b/2 clinical study at the Big Ten Cancer Research Consortium to evaluate Biothera’s Imprime PGG in combination with the Merck anti-PD-1 therapy, Keytruda (pembrolizumab), in second-line non-small cell lung cancer. Read More »
Cidara Therapeutics Inc., a biotechnology company with a focus on developing anti-infective immunotherapies, recently published data from a study analyzing its next-generation echinocandin agent as a comparison to the treatment for intra-abdominal candidiasis. Read More »
Novartis, an immunology and dermatology company, recently reported positive five-year efficacy and safety results for Cosentyx after completing a Phase III long-term extension study in patients with moderate-to-severe plaque psoriasis. Read More »
Spectrum Pharmaceuticals Inc., a biotechnology company focusing on hematology and oncology, recently completed enrollment for its Rolontis Phase 3 Advance pivotal study. Read More »
Pfizer Inc. recently announced positive results for its Reflections B7391003 study, which evaluated the safety and efficacy of PF-06439535 as compared to Avastin (bevacizumab). Read More »
Thermo Fisher Scientific Inc. recently announced the availability of a fully integrated solution for polymer-based drug implant development and production using hot melt extrusion (HME). Read More »
New Jersey-based Merck recently introduced Renflexis (infliximab-abda) in the United States as a biosimilar of Remicade (infliximab) following its FDA approval last April for all eligible indications. Read More »
Pharmaceutical provider AmerisourceBergen recently unveiled the DIR Fee Estimator, its newest tool in conjunction with its nationwide Good Neighbor Pharmacy network, to streamline transactions between provider networks and pharmacy benefit managers by providing cost estimate ranges. Read More »
Amgen and UCB recently announced that their Evenity study, which analyzed the drug as a treatment for postmenopausal women with osteoporosis, met both primary endpoints and the secondary endpoint. Read More »
Xynomic Pharma's has initiated a strategic partnership with the University of California San Francisco for a PAX Study – a multi-national, multi-center, randomized Phase 2/3 study of Pazopanib plus Abexinostat, as opposed to Pazopanib monotherapy in patients with locally advanced or metastatic renal cell carcinoma. Read More »
EMD Serono, the biopharmaceutical business of Merck KGaA in the United States and Canada, recently showcased 14 presentations at the 31st Annual Meeting of the Consortium of Multiple Sclerosis Centers, including eight sets of data on Cladribine Tablet, a treatment for patients with relapsing multiple sclerosis. Read More »
Test detects five most commonly misused and abused prescription drugs; five-minute results will facilitate rapid interventions in prescription drug abuse. Read More »
The last patient in the Phase II BEKINDA (RBH-102) study has completed the treatment and follow-up, RedHill Biopharma Ltd. announced on Monday. Read More »
Shifting from a “pill-centric to patient-centric” focus, cloud-based prescription service is now available for North Carolina consumers — enabling streamlined information sharing and care coordination — provider PrescribeWellness announced recently from its hub in Irvine, California. Read More »
AbbVie recently announced positive follow-up results for its pivotal Phase 3 Resonate trial, which evaluated Imbruvica as a treatment for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). Read More »
Amgen's Xgeva Phase 3 study, the largest international multiple myeloma trial ever conducted, met its primary endpoint by demonstrating that the drug is non-inferior to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma. Read More »
Amgen's Phase 2 study evaluating Imlygic combined with Yervoy as a treatment for patients with unresectable Stage IIIB-IV met its primary endpoint. Read More »
Sanofi and Regeneron Pharmaceuticals Inc. recently announced positive results for a Phase 1 study evaluating investigational REGN2810, a checkpoint inhibitor targeting PD-1 (programmed death 1) in patients with advanced cutaneous squamous cell carcinoma. Read More »
Specialists at information analytics company Elsevier recently announced that its 2017 season for “The Hive,” its source for rising biotech and pharmaceutical companies, is gearing up with unlimited nomination spots now open for aspiring entrants. Read More »
Alerts Sign-up
